Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)

• Status: Completed
• Trial end date: 2019-01-14
• Target enrollment: 0
• Participant gender: All

Summary

An open label, randomized controlled trial of single vs. multiple treatments of praziquantel in intestinal African schistosomiasis in Côte d'Ivoire

This study aims to determine the efficacy of repeated (up to four times) praziquantel treatment against S. mansoni infection in school-age children from Côte d'Ivoire using the traditional Kato-Katz thick smear technique, but also with more accurate and non-invasive antigen- and DNA-detection methods.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Leiden University Medical Center
• Collaborators: Centre Suisse de Recherches Scientifiques en Cote d'Ivoire; Swiss Tropical & Public Health Institute
• Treatments: Praziquantel

Criteria

Inclusion Criteria:

• Subject has a confirmed S. mansoni infection (positive POC-CCA test result and at least one positive out of triplicate Kato-Katz thick smears)

• Subject is aged between 5 and 18 years and otherwise in good health

• Subject has received no recent praziquantel treatment in the past month

• Subject has provided oral assent and provided written informed consent signed by parents/legal guardian

• Subject is able and willing to provide multiple stool and urine samples during study

Exclusion Criteria:

• Known allergy to study medication (i.e. praziquantel and albendazole)

• Pregnancy

• Lactating